CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Study of Efficacy & Safety of Lapatinib & Epirubicin & Cyclophosphamide (EC90) Followed by Paclitaxel & Lapatinib Compared With EC90 Followed by Paclitaxel & Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01205217
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:32.969573+00:00
Published At: 2017-06-07T00:00:00+00:00
Record Updated At: 2017-06-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Neoplasms, Breast"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-06-07"
protocolSection.identificationModule.nctId: "NCT01205217"
protocolSection.identificationModule.officialTitle: "Randomized Study of Efficacy \u0026 Safety of Lapatinib \u0026 Epirubicin \u0026 Cyclophosphamide (EC90) Followed by Paclitaxel \u0026 Lapatinib Compared With EC90 Followed by Paclitaxel \u0026 Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer."
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.